Scientific deep-dive

Tirzepatide Versus Semaglutide on Mood

Across more than 85,000 matched pairs over two years, psychiatric outcomes were the same for both drugs. Against older GLP-1s, semaglutide was associated with about half the hazard of suicidal ideation.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
5 min read·1 citation

People choosing between these two drugs often want to know whether one is harder on mood. A study of more than 85,000 matched pairs followed for two years gives an unusually clean answer: no difference. The composite psychiatric outcome came out at 0.984 in year one and 1.002 in year two.[1]

The head-to-head

Hazard ratios that land on 0.98 and 1.00 across two years, in a sample that size, are about as close to a true null as observational data produces. Whatever separates these two drugs, psychiatric risk over two years does not appear to be it.[1]

There is one wobble, and it is going to be misreported. Tirzepatide showed a nominally higher anxiety hazard in year two: 1.052, with a 95% confidence interval of 1.001 to 1.106. The lower bound clears no effect by one thousandth. The authors say explicitly that it should be interpreted cautiously given multiple comparisons. If you see “tirzepatide raises anxiety risk” anywhere, that is this number, stripped of its own paper’s caveat. The trial and label record on anxiety is in GLP-1s and anxiety.

The comparison that did show something

Against earlier-generation GLP-1 drugs rather than against tirzepatide, semaglutide had a lower hazard for every psychiatric outcome measured in year one.

Semaglutide compared with other GLP-1 receptor agonists, year one.
OutcomeHazard ratio
Depression0.811 (95% CI 0.770–0.855)
Anxiety0.915 (95% CI 0.871–0.961)
Suicidal ideation0.488 (95% CI 0.339–0.702)
Composite psychiatric outcome0.866 (95% CI 0.832–0.901)

The suicidal ideation figure matters most, given how much public argument this drug class has attracted on exactly that point. The hazard roughly halves, with an interval nowhere near one.

Where this sits with everything else

Three independent bodies of evidence now point the same way. A Swedish national cohort found semaglutide associated with lower risk of worsening mental illness and the class associated with less self-harm, which we covered in worsening mental illness. This study finds lower psychiatric event rates against older drugs in the class. And a randomized trial in major depressive disorder found no increase in suicidal ideation, covered here.

Pointing the other way is a spontaneous-reporting signal from FDA adverse event data, discussed in the FAERS analysis. That is the weakest design of the four, and the most susceptible to amplification by the news coverage this question generated.

Two cohorts and a randomized trial point one way; spontaneous FDA adverse event reports point the other.

The same caution applies here as everywhere in this class: semaglutide reaching better outcomes than older drugs may reflect who receives the newest and most effective option rather than the molecule. That confound does not touch the tirzepatide comparison, though. Both drugs are current, both are prescribed to similar people, and the answer there was no difference.

Frequently Asked Questions

Neither, on this evidence. Across more than 85,000 matched pairs followed two years, the composite psychiatric outcome was 0.984 in year one and 1.002 in year two, as close to no difference as observational data produces.
That comes from a single year-two figure of 1.052 with a confidence interval whose lower bound is 1.001, which clears no effect by one thousandth. The authors themselves say it should be interpreted cautiously given multiple comparisons.
Compared with earlier-generation GLP-1 drugs, semaglutide was associated with roughly half the rate of suicidal ideation in year one, at a hazard ratio of 0.488 with an interval nowhere near one.
The reports come from spontaneous FDA adverse event data, which is the weakest design available and the most affected by news coverage. Two large cohorts and a randomized trial now point the other way.
For the comparison against older drugs, yes. That confound is live, and semaglutide reaches different patients than exenatide or dulaglutide. It does not apply to the tirzepatide comparison, where both drugs are current and go to similar people, and the answer there was no difference.

References

  1. 1.Chen SC, Wang TJ, Chou CK, et al. Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists Diabetes, Obesity and Metabolism. 2026. PMID: 42420795.

Antidepressants and a GLP-1: Ozempic, Wellbutrin, Lexapro and What the Labels Say

No GLP-1 label names an antidepressant as an interaction, and people on antidepressants lost as much weight on semaglutide as everyone else. The real overlaps: stacked nausea, slowed absorption of tablets, and two bupropion rules.

11 min read

Semaglutide and Motivation

Semaglutide reduced how heavily people with depression discounted effort, while leaving their sensitivity to probability unchanged. That dissociation is what makes the finding hard to dismiss.

5 min read

GLP-1s and Worsening Mental Illness

Semaglutide was associated with 42% lower risk of worsening mental illness in people with depression and anxiety. Exenatide and dulaglutide showed nothing. Four drugs, one class, two very different results.

5 min read

GLP-1s and Antipsychotic Weight Gain: A Trial Cut Short

Semaglutide produced 13.88% weight loss against 0.42% on placebo in people taking clozapine, without altering clozapine levels or psychotic symptoms. The trial ended at 31 of an intended 80 because the drug ran out.

6 min read

When the Primary Endpoint Fails and a Secondary Doesn't

A randomized trial in 72 people with major depressive disorder found no effect on executive function, its primary outcome. A secondary cognition measure cleared p=0.03, and that is the one that will be reported.

5 min read

GLP-1 Drugs and Blood Pressure: How Much It Falls, and What Happens When You Stop

On the FDA labels, systolic blood pressure fell about 4 to 7 points more than placebo on tirzepatide and 3 to 5 on semaglutide. 24-hour monitoring confirmed it, weight loss explained most of it, and in the withdrawal trials much of it came back.

8 min read

Where to get tirzepatide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.9

Luvo Health

Moving between compounded and brand without changing seller

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →